Bacteria for Treatment: Microbiome in Bladder Cancer

Min, Kyung Sok; Kim, Hyun Tae; Lee, Eun Hye; Park, Hansoo; Ha, Yun‐Sok

doi:10.3390/biomedicines10081783

Cited by 9 publications

(4 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expanding on this comparison revealed varying trends in Bacteroidetes and Firmicutes abundance in patients with NAFLD across geographical regions, highlighting the potential influence of dietary habits on the gut microbiota composition. Interestingly, we observed an enrichment of lactic acid-producing bacteria (such as Lactobacillus) in patients with NAFLD, consistent with the microbiome results reported by Min et al (2022) in patients with bladder cancer. Although there is an association between NAFLD and bladder cancer (Bjorkstrom et al, 2022), the complex mechanisms through which NAFLD promotes the occurrence of bladder cancer remain to be fully elucidated.…”

Section: Discussionsupporting

confidence: 91%

The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease

Mai,

Yang,

Xie

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

BackgroundNon-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide, and gut microbes are associated with the development and progression of NAFLD. Despite numerous studies exploring the changes in gut microbes associated with NAFLD, there was no consistent pattern of changes.MethodWe retrieved studies on the human fecal microbiota sequenced by 16S rRNA gene amplification associated with NAFLD from the NCBI database up to April 2023, and re-analyzed them using bioinformatic methods.ResultsWe finally screened 12 relevant studies related to NAFLD, which included a total of 1,189 study subjects (NAFLD, n = 654; healthy control, n = 398; obesity, n = 137). Our results revealed a significant decrease in gut microbial diversity with the occurrence and progression of NAFLD (SMD = −0.32; 95% CI −0.42 to −0.21; p < 0.001). Alpha diversity and the increased abundance of several crucial genera, including Desulfovibrio, Negativibacillus, and Prevotella, can serve as an indication of their predictive risk ability for the occurrence and progression of NAFLD (all AUC > 0.7). The occurrence and progression of NAFLD are significantly associated with higher levels of LPS biosynthesis, tryptophan metabolism, glutathione metabolism, and lipid metabolism.ConclusionThis study elucidated gut microbes relevance to disease development and identified potential risk-associated microbes and functional pathways associated with NAFLD occurrence and progression.

show abstract

Section: Discussionsupporting

confidence: 91%

The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease

Mai,

Yang,

Xie

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Recent evidence suggests that lactic acid-producing bacteria may have therapeutic value in augmenting immunotherapy response in bladder cancer. The presence or addition of Bifidobacterium and Lactobacillus genera in the bladder has been shown to induce apoptosis and provide antitumor properties through immune-mediated mechanisms [ 50 ]. Lactobacillus rhamnosus and Lactobacillus casei have specifically demonstrated anti-proliferative effects on bladder cancer cell lines in vitro and in vivo mouse models; in one study, Lactobacillus casei was even more cytotoxic to bladder cancer cells than BCG because it directly induced necrosis [ 51 , 52 ].…”

Section: Methodsmentioning

confidence: 99%

Section: The Microbiome and Immunotherapy Response In Bladder Cancermentioning

confidence: 99%

The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers

Drobner,

Doppalapudi,

Saraiya

et al. 2024

J Cancer Immunol

View full text Add to dashboard Cite

Introduction & Objective: The role of the microbiome in the development and treatment of genitourinary malignancies is just starting to be appreciated. Accumulating evidence suggests that the microbiome can modulate immunotherapy through signaling in the highly dynamic tumor microenvironment. Nevertheless, much is still unknown about the immuno-oncology-microbiome axis, especially in urologic oncology. The objective of this review is to synthesize our current understanding of the microbiome’s role in modulating and predicting immunotherapy response to genitourinary malignancies. Methods: A literature search for peer-reviewed publications about the microbiome and immunotherapy response in bladder, kidney, and prostate cancer was conducted. All research available in PubMed, Google Scholar, clinicaltrials.gov, and bioRxiv up to September 2023 was analyzed. Results: Significant differences in urinary microbiota composition have been found in patients with genitourinary cancers compared to healthy controls. Lactic acid-producing bacteria, such as Bifidobacterium and Lactobacillus genera, may have value in augmenting BCG responsiveness to bladder cancer. BCG may also be a dynamic regulator of PD-L1. Thus, the combination of BCG and immune checkpoint inhibitors may be an effective strategy for bladder cancer management. In advanced renal cell carcinoma, studies show that recent antibiotic administration negatively impacts survival outcomes in patients undergoing immunotherapy, while administration of CBM588, a live bacterial product, is associated with improved progression-free survival. Specific bacterial taxa, such as Streptococcus salivarius, have been linked with response to pembrolizumab in metastatic castrate-resistant prostate cancer. Fecal microbiota transplant has been shown to overcome resistance and reduce toxicity to immunotherapy; it is currently being investigated for both kidney and prostate cancers. Conclusions: Although the exact mechanism is unclear, several studies identify a symbiotic relationship between microbiota-centered interventions and immunotherapy efficacy. It is possible to improve immunotherapy responsiveness in genitourinary malignancies using the microbiome, but further research with more standardized methodology is warranted.

show abstract

“… 42 The urinary microbiome may play a role in predicting responsiveness to BCG therapy for NMIBC, especially since numerous studies have identified changes in the diversity and abundance of bacteria in the bladder among patients with urothelial carcinoma compared to healthy controls. 43 Several of these studies also demonstrated that certain lactic acid-producing bacteria (such as Lactobacillus rhamnosus and Lactobacillus casei ) have anti-proliferative effects on bladder cancer cell lines in vitro and in vivo mouse models. 44 , 45 Additionally, in a trial of 31 patients treated for NMIBC with intravesical BCG immunotherapy, Sweis et al reported higher relative concentrations of Proteobacteria in patients with tumor recurrence ( P = .035), whereas Lactobacillales were more abundant in patients without tumor recurrence ( P = .049).…”

Section: Applications To Urothelial Carcinomamentioning

confidence: 99%

Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma

Drobner

Lichtbroun

Singer

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Modern advances in genomic and molecular technologies have sparked substantial research on the human intestinal microbiome over the past decade. A deeper understanding of the microbiome has illuminated that dysbiosis, or a disruption in the microbiome, is associated with inflammatory disease states and carcinogenesis. Novel therapies that target the microbiome and restore healthy flora may have value in dampening the immunopathologic state induced by dysbiosis. A narrative review of the literature on the use of microbiota-centered interventions (MCIs) was conducted. Several randomized clinical trials show that MCIs can augment response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic cancer. Clinical trials have also demonstrated that modulation of the intestinal microbiome can enhance recovery and reduce infectious complications in the surgical management of colorectal adenocarcinoma. Overall, these major discoveries suggest future clinical applications of MCIs for a wide range of immune-mediated conditions. These results may also translate to improved patient outcomes in systemic immunotherapy for urothelial carcinoma as well as in patients recovering from radical cystectomy (RC), which is complicated by high infection rates. Further research is needed to evaluate the optimal bacterial composition of microbiota-centered therapies and the specific cellular changes that lead to improved tumor antigen recognition after microbiota-centered therapies.

show abstract

Bacteria for Treatment: Microbiome in Bladder Cancer

Cited by 9 publications

References 88 publications

The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease

The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease

The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers

Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma

Contact Info

Product

Resources

About